Systematic review of TNFα-induced paradoxical psoriasis: Treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients

References

• Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γexpressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–577.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Thyssen JP, Burisch J, et al. Incidence and risk of inflammatory bowel disease in patients with psoriasis—a nationwide 20-Year cohort study. J Invest Dermatol. 2019;139(2):316–323.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, et al. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016;25(14):1520–1531.
   PubMed Web of Science ®Google Scholar
• Ezzedine K, Visseaux L, Cadiot G, et al. Ustekinumab for skin reactions associated with antitumor necrosis factor-α agents in patients with inflammatory bowel diseases: a single-center retrospective study. J Dermatol. 2019;46(4):322–327.
   PubMed Web of Science ®Google Scholar
• Boggs J, Ramsay B, Lynch M. Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy. Clin Exp Dermatol. 2021;46(3):580–582.
   PubMed Web of Science ®Google Scholar
• Dolinger MT, Rolfes P, Spencer E, et al. Outcomes of children with inflammatory bowel disease who develop anti-Tumor necrosis factor induced skin reactions. J Crohns Colitis. 2022;16(9):1420–1427.
   Google Scholar
• Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-Tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253–260.
   PubMed Web of Science ®Google Scholar
• George LA, Gadani A, Cross RK, et al. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci. 2015;60(11):3424–3430.
   PubMed Web of Science ®Google Scholar
• Gold SL, Cohen-Mekelburg S, Schneider Y, et al. Management of severe anti-tumor necrosis factor (TNF) induced psoriasis in patients with inflammatory bowel disease. American Journal of Gastroenterology. 2016;111:S827.
   Web of Science ®Google Scholar
• Guerra I, Pérez-Jeldres T, Iborra M, Spanish GETECCU group (ENEIDA project), et al. …. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.
   PubMed Web of Science ®Google Scholar
• Hirsch A, Colman RJ, Lang GD, et al. Successful treatment of ulcerative colitis with vedolizumab in a patient with an Infliximab-Associated psoriasiform rash. ACG Case Rep J. 2015;2(4):236–238.
   PubMedGoogle Scholar
• Kodama S, Gupta D, Sullivan E, et al. Prevalence of paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFI) in children - results from a single tertiary center. Research Square Preprints. 2022. DOI:10.21203/rs.3.rs-133378/v1
   Google Scholar
• Olbjørn C, Rove JB, Jahnsen J. Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: a case series and review of the literature. Paediatr Drugs. 2020;22(4):409–416.
   PubMed Web of Science ®Google Scholar
• Pijls PA, Gilissen LP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects. Dig Liver Dis. 2016;48(11):1391–1393.
   PubMedGoogle Scholar
• Prieto V, Fernandez A, Velasco A, et al. P368 rare skin disorders in IBD patients treated with anti-tnfs. Journal of Crohn’s and Colitis. 2014;8:S219.
   Web of Science ®Google Scholar
• Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880–888.
   PubMed Web of Science ®Google Scholar
• Sahuquillo-Torralba A. Paradoxical psoriasiform reactions by anti-TNF treated with ustekinumab in patients with inflammatory bowel disease. Journal of the American Academy of Dermatology. 2019;81(4):AB250.
   PubMed Web of Science ®Google Scholar
• Santos S, Gamelas V, Carvalho D, et al. P578 therapeutic strategies in the approach of paradoxical psoriasis in IBD: Experience of a Centre. Journal of Crohn’s and Colitis. 2019;13(Supplement_1):S403–S404.
   Google Scholar
• White B, Holderman W. Vedolizumab resulted in resolution of anti-tumor necrosis factor psoriasis and sustained clinical and endoscopic remission of Crohnʼs colitis. Inflammatory Bowel Diseases. 2016;22:S79.
   Web of Science ®Google Scholar